Schering-Plough, Merck's Vytorin misses study goal
Monday, July 21, 2008 - 16:07
in Health & Medicine
TRENTON, N.J. (AP) -- In the latest disappointment for cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease or lower the need for valve surgery, sending its makers' stock plunging....
Read the whole article on AP Health
More from AP Health
Related
- Heart valves implanted without open-heart surgeryWed, 7 Jan 2009, 14:56:34 EST
- Diseased heart valve replaced through small chest incisionTue, 10 Feb 2009, 15:21:47 EST
- Umbilical cord blood may help build new heart valvesMon, 10 Nov 2008, 16:49:54 EST
- Minimally-invasive aortic valve bypass benefits high-risk elderly patientsThu, 18 Sep 2008, 16:30:26 EDT
- Half of eligible patients not getting mitral valve surgery, U-M study showsFri, 11 Sep 2009, 10:57:14 EDT